Research programme: neurological disorders - Weizmann Institute of Science/ Health Research Institute of Santiago de Compostela

Drug Profile

Research programme: neurological disorders - Weizmann Institute of Science/ Health Research Institute of Santiago de Compostela

Latest Information Update: 19 Jan 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Weizmann Institute of Science
  • Class Enzymes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Glioblastoma; Stroke

Most Recent Events

  • 10 Dec 2015 Weizmann Institute of Science, Health Research Institute of Santiago de Compostela and Sun Pharma agree to co-develop therapies for the treatment of neurological diseases like brain stroke and glioblastom
  • 10 Dec 2015 Preclinical trials in Glioblastoma in Israel (unspecified route)
  • 10 Dec 2015 Preclinical trials in Stroke in Israel (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top